135 related articles for article (PubMed ID: 21498296)
1. Fat-saturated post gadolinium T1 imaging of the brain in multiple sclerosis.
Al-Saeed O; Ismail M; Athyal R; Sheikh M
Acta Radiol; 2011 Jun; 52(5):570-4. PubMed ID: 21498296
[TBL] [Abstract][Full Text] [Related]
2. Optimizing brain MRI protocols in the follow-up of patients with multiple sclerosis T2-weighted MRI of the brain after the administration of gadopentetate dimeglumine.
Taschner CA; Kirsch EC; Scheffler K; Wetzel SG; Schulte-Mönting J; Kappos L; Radü EW
Magn Reson Imaging; 2005 Apr; 23(3):469-74. PubMed ID: 15862648
[TBL] [Abstract][Full Text] [Related]
3. Early contrast-enhanced magnetic resonance imaging with fluid-attenuated inversion recovery in multiple sclerosis.
Kataoka H; Taoka T; Ueno S
J Neuroimaging; 2009 Jul; 19(3):246-9. PubMed ID: 19021828
[TBL] [Abstract][Full Text] [Related]
4. Uncovering and characterizing multiple sclerosis lesions: the aid of fluid-attenuated inversion recovery images in the presence of gadolinium contrast agent.
Bagnato F
J Neuroimaging; 2009 Jul; 19(3):201-4. PubMed ID: 19187471
[No Abstract] [Full Text] [Related]
5. Multiple sclerosis disease activity correlates with gadolinium-enhanced magnetic resonance imaging.
Gonzalez-Scarano F; Grossman RI; Galetta S; Atlas SW; Silberberg DH
Ann Neurol; 1987 Mar; 21(3):300-6. PubMed ID: 3606036
[TBL] [Abstract][Full Text] [Related]
6. Clinical-magnetic resonance imaging correlations in multiple sclerosis.
Zivadinov R; Leist TP
J Neuroimaging; 2005; 15(4 Suppl):10S-21S. PubMed ID: 16385015
[TBL] [Abstract][Full Text] [Related]
7. A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis.
Rovira A; Swanton J; Tintoré M; Huerga E; Barkhof F; Filippi M; Frederiksen JL; Langkilde A; Miszkiel K; Polman C; Rovaris M; Sastre-Garriga J; Miller D; Montalban X
Arch Neurol; 2009 May; 66(5):587-92. PubMed ID: 19433658
[TBL] [Abstract][Full Text] [Related]
8. Magnetic resonance imaging advances in multiple sclerosis.
Bakshi R
J Neuroimaging; 2005; 15(4 Suppl):5S-9S. PubMed ID: 16385014
[TBL] [Abstract][Full Text] [Related]
9. Characteristic neuroimaging in patients with tumefactive demyelinating lesions exceeding 30 mm.
Kiriyama T; Kataoka H; Taoka T; Tonomura Y; Terashima M; Morikawa M; Tanizawa E; Kawahara M; Furiya Y; Sugie K; Kichikawa K; Ueno S
J Neuroimaging; 2011 Apr; 21(2):e69-77. PubMed ID: 20572907
[TBL] [Abstract][Full Text] [Related]
10. Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years.
Bagnato F; Jeffries N; Richert ND; Stone RD; Ohayon JM; McFarland HF; Frank JA
Brain; 2003 Aug; 126(Pt 8):1782-9. PubMed ID: 12821527
[TBL] [Abstract][Full Text] [Related]
11. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions.
Smith ME; Stone LA; Albert PS; Frank JA; Martin R; Armstrong M; Maloni H; McFarlin DE; McFarland HF
Ann Neurol; 1993 May; 33(5):480-9. PubMed ID: 8498825
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of contrast-enhanced fluid-attenuated inversion-recovery and delayed contrast-enhanced brain MRI in multiple sclerosis.
Bagheri MH; Meshksar A; Nabavizadeh SA; Borhani-Haghighi A; Ashjazadeh N; Nikseresht AR
Acad Radiol; 2008 Jan; 15(1):15-23. PubMed ID: 18078903
[TBL] [Abstract][Full Text] [Related]
13. [Neuroimaging in multiple sclerosis].
Rivera VM
Rev Neurol; 2001 Feb 1-15; 32(3):283-5. PubMed ID: 11310287
[TBL] [Abstract][Full Text] [Related]
14. [The characteristics of enhanced gadolinium DTPA brain magnetic resonance images in 298 multiple sclerosis patients].
Zhang H; Xu XH; Zhao ZG; Guo H; Qiao LY; Yin J; Hou SF; Wei XF; Wen SG; Geng Y; Jiao YJ; Liu JH; Wang H
Zhonghua Nei Ke Za Zhi; 2003 Jul; 42(7):490-1. PubMed ID: 12921611
[TBL] [Abstract][Full Text] [Related]
15. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA.
Paolillo A; Piattella MC; Pantano P; Di Legge S; Caramia F; Russo P; Lenzi GL; Pozzilli C
J Neurol; 2004 Apr; 251(4):432-9. PubMed ID: 15083288
[TBL] [Abstract][Full Text] [Related]
16. Lesion enhancement diminishes with time in primary progressive multiple sclerosis.
Khaleeli Z; Ciccarelli O; Mizskiel K; Altmann D; Miller DH; Thompson AJ
Mult Scler; 2010 Mar; 16(3):317-24. PubMed ID: 20203148
[TBL] [Abstract][Full Text] [Related]
17. Characterization of brain lesions in a mouse model of progressive multiple sclerosis.
Levy H; Assaf Y; Frenkel D
Exp Neurol; 2010 Nov; 226(1):148-58. PubMed ID: 20736006
[TBL] [Abstract][Full Text] [Related]
18. [Magnetic resonance imaging of disseminated sclerosis].
Christiansen AP; Wanscher B; Larsson HB; Henriksen O
Ugeskr Laeger; 1994 Oct; 156(43):6348-52. PubMed ID: 7810007
[TBL] [Abstract][Full Text] [Related]
19. Seeing is believing: in vivo evolution of multiple sclerosis pathology with magnetic resonance.
Ge Y
Top Magn Reson Imaging; 2006 Aug; 17(4):295-306. PubMed ID: 17415002
[TBL] [Abstract][Full Text] [Related]
20. [Neuroimaging and functional analyses for multiple sclerosis].
Kira J
Rinsho Byori; 2000 Sep; 48(9):814-22. PubMed ID: 11051795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
